Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-17T12:55:03.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The displayed ClinicalTrials.gov revision changes from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-10T13:13:17.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    A new page revision label (v3.7.0) is added to the record history, replacing the previous v3.6.6 label. This reflects a minor update to the revision metadata of the study page.
    Difference
    0.1%
    Check dated 2026-09-19T18:21:58.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The record history now includes a new Revision: v3.6.6 entry, and the previous Revision: v3.6.5 entry was removed from the list.
    Difference
    0.1%
    Check dated 2026-08-29T18:18:10.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Newest history entry shows Revision: v3.6.5 in the version list. This change is a small metadata update to the study record.
    Difference
    0.1%
    Check dated 2026-08-15T10:56:14.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    New revision entry added: v3.6.4 replaces v3.6.3 in the history. This reflects an update to the record's version history without changing content or study details.
    Difference
    0.1%
    Check dated 2026-07-25T05:15:57.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.